CN102209705A - 芬戈莫德盐酸盐的结晶形式 - Google Patents

芬戈莫德盐酸盐的结晶形式 Download PDF

Info

Publication number
CN102209705A
CN102209705A CN200980144998XA CN200980144998A CN102209705A CN 102209705 A CN102209705 A CN 102209705A CN 200980144998X A CN200980144998X A CN 200980144998XA CN 200980144998 A CN200980144998 A CN 200980144998A CN 102209705 A CN102209705 A CN 102209705A
Authority
CN
China
Prior art keywords
salt
fty720
peak
weak
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980144998XA
Other languages
English (en)
Chinese (zh)
Inventor
M·马兹
G·约尔丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201710377640.8A priority Critical patent/CN107233336A/zh
Priority to CN201510141353.8A priority patent/CN104788325A/zh
Publication of CN102209705A publication Critical patent/CN102209705A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200980144998XA 2008-11-11 2009-11-10 芬戈莫德盐酸盐的结晶形式 Pending CN102209705A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710377640.8A CN107233336A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式
CN201510141353.8A CN104788325A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168865.7 2008-11-11
EP08168865 2008-11-11
PCT/EP2009/064891 WO2010055028A2 (en) 2008-11-11 2009-11-10 Organic compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201510141353.8A Division CN104788325A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式
CN201710377640.8A Division CN107233336A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式

Publications (1)

Publication Number Publication Date
CN102209705A true CN102209705A (zh) 2011-10-05

Family

ID=40521487

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200980144998XA Pending CN102209705A (zh) 2008-11-11 2009-11-10 芬戈莫德盐酸盐的结晶形式
CN201710377640.8A Pending CN107233336A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式
CN201510141353.8A Pending CN104788325A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710377640.8A Pending CN107233336A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式
CN201510141353.8A Pending CN104788325A (zh) 2008-11-11 2009-11-10 芬戈莫德的结晶形式

Country Status (14)

Country Link
US (2) US8530522B2 (enExample)
EP (1) EP2356090B1 (enExample)
JP (4) JP2012508216A (enExample)
KR (2) KR20130109254A (enExample)
CN (3) CN102209705A (enExample)
AU (1) AU2009315736B2 (enExample)
BR (1) BRPI0921826A2 (enExample)
CA (1) CA2743232C (enExample)
ES (1) ES2643161T3 (enExample)
MX (1) MX2011004962A (enExample)
PL (1) PL2356090T3 (enExample)
PT (1) PT2356090T (enExample)
RU (2) RU2549899C2 (enExample)
WO (1) WO2010055028A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036865A1 (zh) * 2012-09-05 2014-03-13 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN106667981A (zh) * 2017-01-16 2017-05-17 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用
CN106860440A (zh) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗系统性红斑狼疮脑病药物中的应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2746939T3 (es) * 2010-10-01 2020-03-09 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod
MX2013004649A (es) 2010-10-28 2013-06-05 Mapi Pharma Ltd Compuestos intermedios y proceso para la preparacion de fingolimod.
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
ES2746016T3 (es) 2010-12-28 2020-03-04 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
US9216943B2 (en) 2011-04-29 2015-12-22 Dr. Reddy's Laboratories Ltd. Preparation of fingolimod and its salts
US9751834B2 (en) 2011-05-26 2017-09-05 Gri Bio, Inc. Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
WO2012160188A1 (en) 2011-05-26 2012-11-29 Jado Technologies Gmbh Hydroxy-substituted amino and ammonium derivatives and their medical use
DK2809318T3 (da) 2011-05-26 2019-07-22 Gri Bio Inc Ammoniumholdige sulfonsyre-, phosphonsyre- og carboxylsyrederivater og disses medicinske anvendelse
EA028950B1 (ru) 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
WO2013091704A1 (en) * 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
EP2945927A4 (en) * 2013-01-17 2017-01-18 Shilpa Medicare Limited Process for preparation of fingolimod and its salts
JP6484567B2 (ja) 2013-03-05 2019-03-13 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ ２−アミノ−１，３−プロパンジオール化合物およびその塩の製造のための方法
US20160128951A1 (en) 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2020245775A1 (en) * 2019-06-05 2020-12-10 Biocon Limited Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
JP2024521882A (ja) 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
CN1344155A (zh) * 1999-01-27 2002-04-10 概念股份公司 用高适应性的载体经鼻输送/免疫接种
CN1346348A (zh) * 1999-02-10 2002-04-24 卫福有限公司 酰胺化合物及其药物用途
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
WO2004089341A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Organic compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4079505B2 (ja) * 1998-04-28 2008-04-23 田辺三菱製薬株式会社 ２−アミノ−２−［２−（４−オクチルフェニル）エチル］プロパン−１，３−ジオールの新規な製造法
EP1457478B1 (en) * 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
CN1144779C (zh) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
US20030144712A1 (en) * 2001-12-20 2003-07-31 Jackson Streeter, M.D. Methods for overcoming organ transplant rejection
PL372103A1 (en) * 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
CN1212308C (zh) * 2003-07-24 2005-07-27 漆又毛 2－氨基－2－（2－（4－辛基苯基）乙基）－1，3－丙二醇盐酸盐的制备方法
CN1241903C (zh) * 2003-10-14 2006-02-15 马启明 制备2－对辛基苯乙基－2－氨基丙二醇的方法
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
EP1940388A2 (en) * 2005-09-30 2008-07-09 Novartis AG Dpp iv inhibtor for use in the treatment of autoimmune diseases and graft rejection
CN1310869C (zh) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2－氨基－2－[2－(4－烷基苯基)乙基]－1,3－丙二醇的制备方法
CN100548968C (zh) * 2006-03-01 2009-10-14 徐州师范大学 一种制备2-对辛基苯乙基-2-氨基丙二醇盐酸盐的方法
US8318812B2 (en) * 2006-06-02 2012-11-27 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
KR20090057399A (ko) * 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
ES2746939T3 (es) 2010-10-01 2020-03-09 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
CN1344155A (zh) * 1999-01-27 2002-04-10 概念股份公司 用高适应性的载体经鼻输送/免疫接种
CN1346348A (zh) * 1999-02-10 2002-04-24 卫福有限公司 酰胺化合物及其药物用途
WO2004089341A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Organic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASATOSHI KIUCHI等: "Synthesis and Immunosuppressive Activity of 2-Substituted 2-Aminopropane-1,3-diols and 2-Aminoethanols", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
王迷娟: "芬戈莫德(fingolimode)", 《中国新药杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036865A1 (zh) * 2012-09-05 2014-03-13 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN106667981A (zh) * 2017-01-16 2017-05-17 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用
CN106860440A (zh) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗系统性红斑狼疮脑病药物中的应用
CN106667981B (zh) * 2017-01-16 2019-05-14 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用

Also Published As

Publication number Publication date
CA2743232A1 (en) 2010-05-20
US20110229501A1 (en) 2011-09-22
EP2356090A2 (en) 2011-08-17
WO2010055028A3 (en) 2010-07-08
MX2011004962A (es) 2011-05-30
RU2015111229A3 (enExample) 2018-11-08
ES2643161T3 (es) 2017-11-21
RU2015111229A (ru) 2015-11-20
JP2014139179A (ja) 2014-07-31
JP2018035160A (ja) 2018-03-08
RU2011123371A (ru) 2012-12-20
JP2016028056A (ja) 2016-02-25
WO2010055028A2 (en) 2010-05-20
EP2356090B1 (en) 2017-07-05
AU2009315736B2 (en) 2013-08-29
KR20110069156A (ko) 2011-06-22
CA2743232C (en) 2015-12-29
CN107233336A (zh) 2017-10-10
KR20130109254A (ko) 2013-10-07
CN104788325A (zh) 2015-07-22
US8530522B2 (en) 2013-09-10
PT2356090T (pt) 2017-10-16
JP2012508216A (ja) 2012-04-05
RU2549899C2 (ru) 2015-05-10
US20140051766A1 (en) 2014-02-20
PL2356090T3 (pl) 2017-12-29
BRPI0921826A2 (pt) 2016-01-12
AU2009315736A1 (en) 2010-05-20
KR101393994B1 (ko) 2014-05-14

Similar Documents

Publication Publication Date Title
CN102209705A (zh) 芬戈莫德盐酸盐的结晶形式
RU2543621C2 (ru) Соли финголимода
US9682988B2 (en) Solid salt form of α-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
AU2013100532B4 (en) Crystalline forms of fingolimod HCL
AU2013203470A1 (en) Salts of fingolimod

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111005